David J. Borges, Chief Financial Officer and Chief Accounting Officer of Omeros Corp, disposed of 10,906 ordinary shares in open-market transactions valued at $206,804 under a Rule 10b5-1 trading plan established on February 10, 2026.
The sales were executed in two tranches: 10,000 shares at $18.95 each on August 21, 2026, and 906 shares at $19.10 each on August 24, 2026. Concurrently, Borges exercised stock options for 10,906 shares at prices ranging from $2.94 to $3.93, totaling $37,910 in acquisition costs. The options, vesting in 48 equal monthly installments since April 2022 and April 2023, were exercised in the same tranches as the share sales.
The transactions followed Omeros’ second-quarter results, which exceeded analyst expectations. Adjusted earnings reached $0.02 per share, reversing a forecasted loss of $0.25 per share, while revenue climbed to $28.5 million against a projected $12.67 million. The company attributed the outperformance to the commercial launch of YARTEMLEA, a newly approved medication.
